PET/CT Imaging for Therapy Assessment in Multiple Myeloma Including MRD
Cancers · 08.07.2026 · 18 (14) · 2184
DOI: 10.3390/cancers18142184 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 08.07.2026. Verfasst von Alessia Lucia Daverio und 9 weiteren Autor:innen. Beteiligte Einrichtung: Service de Médecine Nucléaire, Département d'Imagerie Médicale, Institut Gustave Roussy, F-94805 Villejuif, France. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Multiple myeloma (MM) is a complex hematologic malignancy characterized by abnormal plasma cell proliferation in the bone marrow. [18F]FDG PET/CT has emerged as a key imaging modality, demonstrating high sensitivity and specificity for the detection of metabolically active disease compared with conventional imaging techniques. This review examines the role of PET/CT imaging in evaluating therapeutic response in symptomatic myeloma, including minimal residual disease (MRD) assessment.
Methods
We surveyed the literature published between 2014 and 2024 across PubMed, Scopus, Web of Science, and the Cochrane Library for peer-reviewed articles evaluating PET imaging in the assessment of treatment response in multiple myeloma. Results: [18F]FDG PET/CT provides a whole-body assessment of disease burden, extramedullary involvement detection, and early metabolic response evaluation. Standardized response assessment criteria (Deauville, IMPeTUs, IMWG) have enhanced the reproducibility and accuracy of treatment monitoring. Semiquantitative parameters including SUVmax and metabolic tumor volume (MTV) provide useful prognostic information with PET negativity correlating with improved progression-free and overall survival. The integration of PET/CT with bone marrow assessment techniques (next-generation flow cytometry and sequencing) optimizes MRD evaluation and patient stratification.
Conclusions
PET/CT represents a valuable imaging tool for improving therapeutic decision making and risk stratification in MM management. Emerging radiotracers beyond FDG, including [11C]choline, [11C]methionine, and targeted agents like [68Ga]pentixafor and CD38-targeted immunoPET tracers, hold promise for enhanced diagnostic capabilities in specific clinical contexts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Service de Médecine Nucléaire, Département d'Imagerie Médicale, Institut Gustave Roussy, F-94805 Villejuif, France.
- Nuclear Medicine Division, AOU Città della Salute e della Scienza di Torino, University of Turin, 10126 Turin, Italy.
- Département d'Hematologie, Institut Gustave Roussy, F-94805 Villejuif, France.
- Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
ORCID-Profile: Alessia Lucia Daverio, Théophraste Henry, Laurentiu Agrigoroaie, Guido Rovera, Silvia Morbelli
Zitieren
APA
Daverio, A. L., Coccarelli, A., Henry, T., Danu, A., Agrigoroaie, L., Trabelsi, K., Kamoun, T., Rovera, G., Morbelli, S., & Deandreis, D. (2026). PET/CT Imaging for Therapy Assessment in Multiple Myeloma Including MRD. Cancers, 18(14), 2184. https://doi.org/10.3390/cancers18142184
Vancouver
Daverio AL, Coccarelli A, Henry T, Danu A, Agrigoroaie L, Trabelsi K, et al. PET/CT Imaging for Therapy Assessment in Multiple Myeloma Including MRD. Cancers. 2026;18(14):2184. doi:10.3390/cancers18142184
BibTeX
@article{Daverio2026,
author = {Daverio, Alessia Lucia and Coccarelli, Alessandro and Henry, Théophraste and Danu, Alina and Agrigoroaie, Laurentiu and Trabelsi, Khalil and Kamoun, Tarek and Rovera, Guido and Morbelli, Silvia and Deandreis, Désirée},
title = {PET/CT Imaging for Therapy Assessment in Multiple Myeloma Including MRD},
journal = {Cancers},
year = {2026},
volume = {18},
number = {14},
pages = {2184},
doi = {10.3390/cancers18142184}
}
EUVIMED